Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

Submitted: July 3, 2017
Accepted: November 5, 2017
Published: December 19, 2017
Abstract Views: 1452
PDF: 841
Supplementary: 199
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


A large number of COPD patients are smokers. The particular characteristics of this group as well as their need to quit usually require psychological counselling and pharmacological treatment to achieve abstinence and, often, intensively. Little information is available about this issue.  The main objective of the study was to evaluate the effectiveness of varenicline after 24 weeks of treatment, with continuous abstinence between weeks 9 and 24.  This study was a post-authorization, open label, observational study of prospective follow-up. Patients included were smokers with severe or very severe COPD criteria who were treated with varenicline for 24 weeks, i.e. with a 12-week extension over the usual treatment.  The outcomes in the population of subjects completing 24 weeks of follow-up were at week 24: continuous abstinence 36.8%, 7 days point prevalence abstinence 65.7%, and continuous smoking 31.5%.The outcomes in the intention-to-treat population included at baseline were: continuous abstinence 17.7% of patients, 7 days point prevalence abstinence 31.6%, continuous smoking 15.1% and not valid/unknown 51.8%.  The mean CAT score at week 24 was 15 and reduction from the baseline was 3.77 (paired T test, p<0.01). The most common adverse events reported were nausea, vivid dreams, stomach ache, insomnia, headache and vomiting.  Patients included in VALUE were active smokers despite all of them had a severe COPD which suggests a very high degree of dependence. Although the study do not allow to infer the results to the global population of smokers with severe COPD, the outcomes have shown that, at 24 weeks follow up 36.8% of the patients were successful in quitting but from 79 patients enrolled initially only 17.7% quit. 



PlumX Metrics


Download data is not yet available.


Supporting Agencies

This study has been conducted by the Tobacco Researching Group of the Spanish Respiratory Society, SEPAR. This Society received an unrestricted grant from Pfizer.

How to Cite

Jiménez-Ruiz, Carlos A., Marcos Garcia Rueda, Manuel A. Martinez Muñiz, Jacobo Sellarés, Maria A. Jiménez-Fuentes, Lourdes Lázaro Asegurado, Esther Rodríguez Gonzalez, Concepción Rodriguez Garcia, Oriol Armengol, Emilia Abad, Teresa Peña, Adolfo Domenech del Rio, and Juan A. Riesco Miranda. 2017. “Varenicline in Smokers With Severe or Very Severe COPD After 24 Weeks of Treatment. A Descriptive Analysis: VALUE Study”. Monaldi Archives for Chest Disease 87 (3).